Welcome to our dedicated page for NEXIMMUNE news (Ticker: NEXI), a resource for investors and traders seeking the latest updates and insights on NEXIMMUNE stock.
NexImmune, Inc. (Nasdaq: NEXI) is an emerging biopharmaceutical company focused on advancing a new generation of immunotherapies using its proprietary Artificial Immune Modulation (AIM™) technology platform. Originally developed at Johns Hopkins University, AIM™ technology harnesses the body’s immune system to orchestrate a targeted T cell response against diseases.
The cornerstone of NexImmune’s innovation is the development of artificial antigen-presenting cells (aAPCs). These aAPCs present specific antigens to T cells, which in turn stimulate a highly targeted immune response. This approach can be rapidly customized to direct immune attacks toward various foreign substances or diseased cells within the patient's body. The company is currently working on therapies aimed at treating cancer and other serious immune-mediated conditions.
NexImmune has two key product candidates in clinical trials: NEXI-001, for treating acute myeloid leukemia (AML), and NEXI-002, for multiple myeloma (MM). These candidates leverage the curative potential of the body’s own T cells, engineered to target and destroy specific cancer cells.
Recent Highlights:
Clinical and Preclinical Updates: NexImmune announced significant progress in generating pre-clinical data supporting their multi-antigen-specific T cell-directing products. This includes validation from collaborators at leading institutions, underlining the transformative potential of their AIM technology.
Financial Highlights: The company recently reported select second-quarter 2023 financial results, showcasing a focus on core capabilities while managing operational flexibility through workforce adjustments.
Partnerships: NexImmune extended its research collaboration with Yale University and JDRF. This partnership aims to explore the use of NexImmune’s AIM nanoparticles combined with anti-CD3 mAb for potential type 1 diabetes treatments. The extension includes an additional $300,000 grant provided by JDRF.
In October 2023, NexImmune executed a 1-for-25 reverse stock split, reducing its outstanding shares and addressing compliance with Nasdaq’s minimum bid price requirement. The company remains dedicated to advancing its innovative therapeutic candidates and remains a significant player in the field of immuno-oncology and beyond.
For more information, visit www.neximmune.com.
NexImmune, a clinical-stage biotechnology company, reported Q1 2022 financial results with a net loss of $15.0 million, translating to a loss per share of $0.66. Cash and equivalents totaled $65.0 million, expected to fund operations into Q2 2023. Clinical updates indicate robust immune responses in NEXI-001 and ongoing trials for NEXI-002, with further data anticipated in 2H 2022. The company plans to submit an IND for NEXI-003 in 1H 2022. Increased R&D expenses reached $10.4 million, reflecting trial costs and personnel growth.
NexImmune, Inc. (Nasdaq: NEXI), in collaboration with JDRF and Yale, has received a $600,000 grant to research the use of its AIM nanoparticles with anti-CD3 mAb for type 1 diabetes (T1D). The two-year study aims to explore the potential for this combination therapy to modulate T cells linked to T1D. Dr. Jack Ragheb of NexImmune highlighted the technology’s capability to target autoreactive T cells. This initiative supports JDRF’s mission to accelerate advancements in T1D treatment.
NexImmune, a clinical-stage biotechnology firm (Nasdaq: NEXI), has appointed Dr. Leena Gandhi, Director at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director. Dr. Gandhi, an expert in immuno-oncology, expressed enthusiasm for advancing NexImmune's novel immunotherapy technology, which aims to enhance targeted immune responses. The company is focused on developing its AIM™ nanoparticle technology for treating various cancers, with two lead programs currently in Phase 1/2 clinical trials for relapsed AML and multiple myeloma.
NexImmune (Nasdaq: NEXI), a clinical-stage biotechnology firm, announced a preclinical research partnership with Columbia University’s Herbert Irving Comprehensive Cancer Center. The collaboration aims to explore the use of NexImmune’s adoptive cell therapy, AIM ACT, in treating HPV-related cancers, particularly head and neck squamous cell carcinoma. This partnership is poised to address significant unmet needs in HPV-associated cancers, leveraging Columbia's innovative patient-derived organoid models to assess therapeutic potential.
NexImmune, Inc. (Nasdaq: NEXI) announced the promotion of Mathias Oelke, Ph.D., to Chief Scientific Officer. A scientific co-founder, Dr. Oelke has over 20 years of experience in cancer immunotherapy and has been instrumental in NexImmune’s progress. He will lead ongoing development of the company's proprietary Artificial Immune Modulation (AIM™) technology, which aims to enhance T cell responses against cancer. NexImmune’s lead clinical programs, NEXI-001 and NEXI-002, are currently in Phase 1/2 trials for treating relapsed AML and multiple myeloma, respectively.
NexImmune and Zephyr AI have announced a strategic partnership to advance T-cell-mediated therapies in oncology. This collaboration will leverage Zephyr's AI technology for target discovery and NexImmune’s AIM platform for validation. The focus is on identifying optimal antigens for potential new cancer therapeutics, aiming to enhance treatment for patients with solid and hematological cancers. The partnership is expected to accelerate drug discovery, reduce costs, and improve patient outcomes through innovative cancer treatment approaches.
NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced a research collaboration with The Laura and Isaac Perlmutter Cancer Center to evaluate its artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific T cells from melanoma patients. The collaboration will be guided by Dr. Jeffrey S. Weber, Deputy Director of the center. The AIM technology platform aims to validate the targeting of neoantigens across various cancers, enhancing the development of innovative therapies for cancer patients.
NexImmune, a clinical-stage biotechnology company, will have its CEO, Kristi Jones, present at the Barclays 2022 Global Healthcare Conference on March 17, 2022, at 8:30 a.m. ET. The presentation will provide insights into the company's innovative immunotherapy approach that utilizes proprietary AIM nanoparticle technology to target T cells for a robust immune response. NexImmune's lead programs, NEXI-001 and NEXI-002, are in clinical trials for treating relapsed AML post-stem cell transplantation and refractory multiple myeloma. A replay will be available for 30 days post-conference.
NexImmune, a clinical-stage biotechnology company, reported significant advancements in 2021, driven by a successful $126.5M IPO. Key highlights include robust immune responses in Phase 1/2 trials of NEXI-001 and NEXI-002, with no severe adverse events, and plans to submit an IND for NEXI-003 in 1H22. Financially, cash reserves increased to $81.8M, enabling operations into Q2 2023, despite a net loss of $50.9M for the year. The company aims to release further clinical updates in the latter half of 2022, showcasing its commitment to advancing immunotherapy treatments.
NexImmune, a clinical-stage biotechnology company, announced the appointment of Kristi Jones as its new Chief Executive Officer following the resignation of Scott Carmer. Jones, who has been with the company since 2017 and previously served as Chief Business Officer and Chief Operating Officer, brings over 25 years of experience in the biotechnology and pharmaceutical sectors. The company is advancing its immunotherapy platform using proprietary AIM™ nanoparticle technology, with lead programs NEXI-001 and NEXI-002 currently in Phase 1/2 trials.
FAQ
What is the current stock price of NEXIMMUNE (NEXI)?
What is the market cap of NEXIMMUNE (NEXI)?
What is NexImmune’s AIM™ technology?
What are NexImmune’s main product candidates?
What recent financial steps has NexImmune taken?
What are the recent clinical and preclinical highlights for NexImmune?
Which universities and organizations is NexImmune collaborating with?
What is the significance of the 1-for-25 reverse stock split?
Where can I find more information about NexImmune?
Who can be contacted for investor relations at NexImmune?
What types of diseases are NexImmune’s therapies targeting?
What potential does NexImmune’s technology hold?
